⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6653526 | 0.97 | — | — | |
| SCHEMBL9761067 | 0.65 | — | — | |
| SCHEMBL19886831 | 0.65 | — | — | |
| SCHEMBL7423144 | 0.65 | — | — | |
| SCHEMBL7265390 | 0.65 | — | — | |
| SCHEMBL3813633 | 0.65 | — | — | |
| SCHEMBL3815061 | 0.62 | — | — | |
| Lithium Ion SCHEMBL8975741 | 0.62 | — | — | |
| SCHEMBL7266247 | 0.60 | — | — | |
| SCHEMBL9744938 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012146067-A1 | 1,4-DIHYDROPYRIDINE -3,5-DICARBOXYLATE DERIVATIVES, PREPARATION METHODS AND USES THEREOF | 山东亨利医药科技有限责任公司 (CN) | 2012-11-01 | — | — | WO | claimed |
| EP-3094333-B1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | Euclises Pharmaceuticals, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. | 2016-11-24 | — | — | US | disclosed |
| EP-3094333-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| WO-2015109011-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. (US) | 2015-07-23 | — | — | WO | disclosed |